HOME >> BIOLOGY >> NEWS
Landmark agreement between Samoa and UC Berkeley could help search for AIDS cure

Apia, Samoa - The University of California, Berkeley, has signed an agreement with the Samoan government to isolate from an indigenous tree the gene for a promising anti-AIDS drug and to share any royalties from sale of a gene-derived drug with the people of Samoa.

The agreement, announced today (Thursday, Sept. 30) in Apia, the capital of Samoa, supports Samoa's assertion of national sovereignty over the gene sequence of Prostratin, a drug extracted from the bark of the mamala tree (Homalanthus nutans). The drug currently is being studied by scientists around the world because of its potential to force the AIDS virus out of hibernation in the body's immune cells and into the line of fire of anti-AIDS drugs now in use.

"Prostratin is Samoa's gift to the world," explained Samoan Minister of Trade Joseph Keil. "We are pleased to accept the University of California as a full partner in the effort to isolate the Prostratin genes."

Despite Prostratin's promise as an anti-AIDS drug, its supply is limited by the fact that the drug has to be extracted from the bark and stemwood of the mamala tree. Researchers in the laboratory of Jay Keasling, UC Berkeley professor of chemical engineering, plan to clone the genes from the tree that naturally produce Prostratin and insert them into bacteria to make microbial factories for the drug. A similar technology is currently being explored to produce the anti-malarial drug artemisinin.

"A microbial source for Prostratin will ensure a plentiful, high-quality supply if it is approved as an anti-AIDS drug," said Keasling, who also is a faculty affiliate with the California Institute for Quantitative Biomedical Research (QB3) and head of the Synthetic Biology Department at Lawrence Berkeley National Laboratory. "We consider the actual gene sequences as part of Samoa's sovereignty, and every effort will be made to reflect this fact."

The agreement, signed by Prime Minister Tuila'epa Aiono Sailele M
'"/>

Contact: Robert Sanders
rls@pa.urel.berkeley.edu
510-643-6998
University of California - Berkeley
30-Sep-2004


Page: 1 2 3

Related biology news :

1. Landmark gene agreement announced by Samoan government and UC Berkeley for anti-AIDS drug Prostratin
2. Landmark, pivotal Phase IIb/III trial of biotoxin for cancer pain begins
3. Landmark conference for United Nations on human cloning and stem cell research
4. Landmark study offers new information about breast cancer genes
5. Landmark completion of comprehensive index of human proteins to be presented at New York Academy of Sciences
6. Radical discovery dedicated a National Historic Chemical Landmark
7. Landmark obesity study
8. Landmark progress in understanding ribosome structure-- research done at Brookhaven Labs light source
9. NSF and AIBS sign cooperative agreement for NEON project office
10. UN report: Accelerate global agreement to oversee exploitation of South Pole extremophiles
11. Cyrospace, University of Houston sign commercialization agreement

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/6/2019)... , ... November 06, 2019 , ... ... a new podcast to provide information to patients about a poorly disclosed deficiency ... are given without knowing the dose of the treating stem cells. This ...
(Date:11/5/2019)... N.J. (PRWEB) , ... November 05, 2019 , ... ... development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, ... being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019. ...
(Date:11/2/2019)... (PRWEB) , ... October 31, 2019 , ... In this ... with a successful career in research and consulting. , The Beyond the Lab Podcast ... episodes feature interviews from alumni who have jobs in the biomedical field — and ...
Breaking Biology News(10 mins):
(Date:10/26/2019)... ... October 24, 2019 , ... Sparks Marketing Group, Inc. ... (BMMG), a boutique healthcare-specific marketing firm, to strengthen the agency’s growing focus on ... , Healthcare clients in pharma, bio-therapeutics, medical device and healthcare technologies currently account ...
(Date:10/22/2019)... ... , ... DermBiont, a clinical stage microbiome biotechnology company developing ... safety endpoints, with no application site reactions and no adverse events, in a ... tinea pedis (athlete’s foot). Additionally, the trial demonstrated a clinical response with improvement ...
(Date:10/10/2019)... ... October 09, 2019 , ... The ... Principal Deputy Commissioner, FDA, as a newly-confirmed keynote speaker for the 2019 ... Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist and palliative medicine physician, is ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... Project (TMP), Madhumita Suresh and Leslie Maurer presented company executives with a set ... and Science (MBS) graduates will offer insights from their TMP to a wider ...
Breaking Biology Technology:
Cached News: